Novel strategy in lupus therapy: From the peptide P140 to Lupuzor™;Du peptide P140 au Lupuzor™, un futur médicament pour le lupus ?

Annales Pharmaceutiques Francaises

Volumn 69, Issue 3, 2011, Pages 151-154

  Muller, S ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Clinical trial; Immunomodulation; Lupus mouse model; Systemic lupus erythematosus; Therapeutic peptide

Indexed keywords

FORIGERIMOD; PEPTIDE P140; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; SPLICEOSOMAL PEPTIDE P140;

AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; IMMUNOCOMPROMISED PATIENT; LUPUS VULGARIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SHORT SURVEY; ANIMAL; CLINICAL TRIAL; DISEASE MODEL; HUMAN; MOUSE; MULTICENTER STUDY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PEPTIDE FRAGMENTS;

EID: 79955883535     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.01.006     Document Type: Short Survey

References (15)

1. Monneaux F., Muller S. Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res. Ther 2009, 11:234.
2. Briand J.P., Muller S. Emerging peptide therapeutics for inflammatory autoimmune diseases. Curr. Pharmaceutical Design 2010, 16:1136-1142.
3. Monneaux F., Briand J.P., Muller S. B and T cell immune response to snRNP in lupus mice. Autoreactive CD4+ T cells recognize a T cell epitope located within the conserved RNP consensus sequence of the 70K protein. Eur. J. Immunol 2000, 20:2191-2200.
4. Woppmann A., Will C.L., Kornstadt U., Zuo P., Manley J.L., Lührmann R. Identification of an snRNP-associated kinase activity that phosphorylates arginine/serine rich domains typical of splicing factors. Nucleic Acids Res 1993, 21:2815-2822.
5. Monneaux F., Lozano J.M., Patarroyo ME., Briand J.P., Muller S. T cell recognition and therapeutic effects of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr lupus mice. Eur. J. Immunol 2003, 33:287-296.
6. Monneaux F., Hoebeke J., Sordet C., Nonn C., Briand J.-P., Maillère B., et al. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analogue. J. Immunol 2005, 175:5839-5847.
7. Monneaux F., Parietti V., Briand J.P., Muller S. Intramolecular T cell spreading in unprimed MRL/lpr mice: importance of the U1-70K protein sequence 131-151. Arthritis Rheum. 2004, 50:3232-3238.
8. Monneaux F., Parietti V., Briand J.P., Muller S. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res. Ther 2007, 9:R111.
9. Page N., Schall N., Strub J.M, Quinternet M., Chaloin O., Décossas M., et al. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by T cells. PloS ONE 2009, 4:e5273.
10. Page N., Gros F., Schall N., Décossas M., Bagnard D., Briand J.P. and Muller S. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogeneous MHCII presentation in murine lupus. Ann. Rheum Dis 2010. [Epub ahead of print]. doi:10.1136/ard.2010.139832.
11. Muller S., Monneaux F., Schall N., Rashkov R.K., Oparanov B.A, Wiesel P., et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus. Results of an early phase II clinical trial. Arthritis Rheum 2008, 58:3873-3883.
12. Dieker J., Cisterna B., Monneaux F., Décossas M., van der Vlag J., Biggiogera M., et al. Apoptosis changes the phosphorylation status and subcellular localization of the spliceosomal autoantigen U1-70K. Cell Death Diff 2008, 15:793-804.
13. Utz P.J., Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998, 41:1152-1160.
14. Rosen A., Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Diff 1999, 6:6-12.
15. Rodenburg R.J.T., Raats J.M.T., Pruijn G.J.M., van Venrooij W.J. Cell death: a trigger of autoimmunity?. BioEssays 2000, 22:627-636.